Levetiracetam + Placebo

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Levodopa Induced Dyskinesia

Conditions

Levodopa Induced Dyskinesia

Trial Timeline

May 1, 2006 → Oct 1, 2007

NCT ID

NCT00291733

About Levetiracetam + Placebo

Levetiracetam + Placebo is a phase 2 stage product being developed by UCB for Levodopa Induced Dyskinesia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00291733. Target conditions include Levodopa Induced Dyskinesia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00291213	Phase 3	Completed	—	—	Tardive Dyskinesia
NCT01228747	Phase 3	Completed	Oct 1, 2010	May 1, 2014	Epilepsy
NCT00566046	Phase 3	Terminated	Nov 1, 2007	May 1, 2010	Epilepsy, Post-Traumatic
NCT00291733	Phase 2	UNKNOWN	May 1, 2006	Oct 1, 2007	Levodopa Induced Dyskinesia
NCT00254657	Pre-clinical	Completed	Mar 1, 2004	Apr 1, 2005	Fibromyalgia
NCT00615615	Phase 3	Completed	Sep 1, 1999	Mar 1, 2003	Epilepsy

Competing Products

1 competing product in Levodopa Induced Dyskinesia

See all competitors

Product	Company	Stage	Hype Score
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation	Sumitomo Pharma	Phase 1	29